ASX ANNOUNCEMENT

ARGENICA APPOINTS VICE PRESIDENT OF REGULATORY AFFAIRS

Perth, Australia; 6 August, 2025 – Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other neurological conditions, is pleased to announce it has appointed Sharon Hanegraaf as Vice President of Regulatory Affairs. Sharon will lead Argenica's regulatory affairs activities, including regulatory submissions such as investigational new drug applications to the Food and Drug Administration (FDA) and regulatory incentives including orphan drug designations, and fast track designations. At the outset Sharon will work closely with Argenica's VP of Clinical Development, Dr Meghan Thomas as the Company plans for regulatory approvals to commence later stage clinical trials in acute ischaemic stroke.

Sharon is a highly experienced biotechnology executive with an extensive background in regulatory affairs across global jurisdictions. With close to 30 years of experience in international drug development, Sharon specialises in managing all regulatory activities for pharmaceuticals transitioning from early stage to late-stage development through to registration. Sharon has played pivotal roles in advancing compounds from preclinical through Phase 3 clinical, and product registration, with extensive experience in numerous successful regulatory submissions, including Investigational New Drug (IND) Applications, and New Drug Applications (NDA). Sharon has conducted multiple direct face-to-face negotiations with regulatory authorities, including the US Food and Drug Administration, the Australian Therapeutic Goods Association, and various European regulatory authorities.

Sharon is joining Argenica from Kinoxis Therapeutics where she was the Vice President of Drug Development & Strategy, having successfully executed their inaugural IND application and leading numerous regulatory interactions. Previous positions include regulatory affairs specialist roles at Prota Therapeutics, Facet Life Sciences, Neuren Pharmaceuticals and Acrux.

Dr Liz Dallimore, **Argenica's Managing Director**, said: "We are delighted to have Sharon join Argenica as our Vice President of Regulatory Affairs. Sharon has extensive experience in successfully executing regulatory strategy, including opening numerous INDs and successful marketing authorisations with the US FDA. This appointment comes at a pivotal time for Argenica as we look to progress ARG-007 into later stage acute ischaemic stroke trials and develop our clinical program in traumatic brain injury. Sharon's extensive regulatory expertise will be an important addition to our existing highly skilled team."

Sharon will commence with the Company on 11 August 2025 in a full-time capacity.

This announcement has been approved for release by the Managing Director and Company Secretary.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has now initiated a Phase 2 clinical trial in acute ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.